The BRPF3 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the BRPF3 gene in SK-HEP-1 cells. This pooled format maintains population-level heterogeneity while generating a functional loss of BRPF3, providing a robust model for studying gene function without clonal selection artifacts. The polyclonal nature ensures broad coverage of editing outcomes, making it suitable for population-based functional genomics applications.
SK-HEP-1 is a human malignant hepatic epithelial cell line derived from liver adenocarcinoma. Widely used in hepatocellular carcinoma (HCC) research, these cells display aggressive tumorigenic properties, including rapid proliferation and high metastatic potential, offering a physiologically relevant backdrop for investigating epigenetic determinants of liver cancer progression.
BRPF3 acts as a structural scaffold within the MOZ/MORF histone acetyltransferase complexes, directly interacting with KAT6A, KAT6B, ING5, and EAF6. It facilitates acetylation of histone H3K14 and H3K23 through its bromodomain and PHD finger, linking upstream regulators such as MYC, SP1, and MAPK signaling to chromatin remodeling. Downstream, BRPF3-dependent acetylation activates transcription of genes involved in cell cycle control, apoptosis, HOX clusters, and TP53, positioning it as a key node in growth-regulatory gene networks.
In HCC cells, BRPF3-mediated acetylation sustains oncogenic transcriptional programs. Disrupting BRPF3 in SK-HEP-1 is expected to reduce H3K14ac and H3K23ac at promoters of MYC targets and tumor-suppressor pathways, impairing proliferation and enhancing vulnerability to chemotherapeutics. This knockout model thus enables dissection of BRPF3??s role in hepatic tumor maintenance and drug response.
Applications include RNA-seq, ChIP-qPCR, and western blotting to assess epigenetic and expression changes, as well as cell proliferation, migration, and drug sensitivity assays for functional phenotyping. The polyclonal knockout cells are suited for CRISPR screening and validation of epigenetic targets in liver cancer. For additional product details or custom requests, please contact Ascent Research.
